The key idea is comparing how much each thrombotic risk factor raises the chance of a clot relative to people without the factor. Inherited deficiencies of Protein C, Protein S, or Antithrombin impair natural anticoagulation and raise thrombosis risk to roughly 2.8 times higher than controls. Antiphospholipid antibodies (APLA) also increase risk but to a lesser extent, about 2 times higher. The option that states about 2.8-fold for the deficiencies and about 2-fold for APLA best matches these approximate figures. The other choices propose numbers that are either too high, too low, or swapped, making them less consistent with the given data.

Replenishing iron stores with oral therapy takes months, not just weeks. While hemoglobin often begins to rise quickly once therapy starts, the body’s iron reserves (ferritin stores) require a longer, steady input of iron to be rebuilt. With standard oral iron, the usual course is enough to restore depleted stores over several months—typically around half a year. The exact duration depends on ongoing blood loss, absorption, dosage, and adherence. You monitor progress by checking ferritin and iron indices, continuing therapy until stores are replenished even after hemoglobin has normalized. Shorter courses may raise Hb but leave stores depleted, while longer courses are needed if losses persist or absorption is poor.

Warfarin is cleared mostly by the liver. The liver metabolizes warfarin through hepatic cytochrome P450 enzymes into inactive metabolites that are then eliminated, with the drug’s effect arising from its action in the liver itself. Warfarin blocks vitamin K–dependent gamma-carboxylation of clotting factors produced in the liver, so the factors that are made are not properly carboxylated and remain inactive. Because the primary processing and clearance of warfarin occur in the liver, it is the major organ responsible for elimination. The kidneys, lungs, and spleen are not the main routes of warfarin metabolism or clearance.

The Direct Antiglobulin Test looks for immune components that are already attached to a patient’s red blood cells. In this test, the red cells are washed, then an anti-human globulin reagent is added. If the cells have antibodies (usually IgG) or complement (such as C3) bound to their surface in vivo, the anti-globulin causes the cells to agglutinate. A positive result therefore indicates that the red cells are coated with immunoglobulin or complement, which supports immune-mediated hemolysis (for example, autoimmune hemolytic anemia, transfusion reactions, or hemolytic disease of the newborn). This is distinct from tests that detect red cell antigens, measure HbA1c, or detect antibodies in plasma, which are addressed by other assays.

Warfarin is used for long-term oral anticoagulation in patients who have a high risk of thrombosis from either prosthetic material or autoimmune thrombophilia. The two classic first-line indications are mechanical heart valves and antiphospholipid syndrome with a history of thrombosis. Mechanical heart valves create a surface that readily promotes clot formation, so lifelong anticoagulation with warfarin is essential to prevent valve thrombosis and systemic embolism, with target INR requirements that vary by valve type and position. In antiphospholipid syndrome, especially after a thrombotic event, long-term warfarin reduces the risk of recurrent thrombosis more reliably than alternatives in many cases, guiding ongoing therapy with a therapeutic INR. In contrast, warfarin is avoided in pregnancy due to teratogenicity, and while DVT and atrial fibrillation are common indications for anticoagulation, the two strongest and most definitive scenarios for warfarin use are mechanical valves and antiphospholipid–related thrombosis.